Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.64 |
| ▸ | TDO2 | P48775 | 19/20 | 0.64 |
| ▸ | IDO2 | Q6ZQW0 | 8/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26614083 | 0.93 | IDO1 (0.58) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL30639096 | 0.89 | IDO1 (0.63) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL26857224 | 0.87 | IDO1 (0.68) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL26614281 | 0.87 | IDO1 (0.70) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL26614090 | 0.87 | IDO1 (0.71) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL26614110 | 0.86 | IDO1 (0.46) | IDO1TDO2IDO2 | |
| SCHEMBL26614293 | 0.84 | IDO1 (0.68) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL26614172 | 0.84 | IDO1 (0.67) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL26614192 | 0.82 | IDO1 (0.65) | IDO1TDO2IDO2MEN1APAF1 | |
| SCHEMBL31382861 | 0.80 | IDO1 (0.77) | IDO1TDO2IDO2MEN1APAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |